osteoporosis-arthroplasty-2017-posters-abstracts

10 / 21

Page 63
Notes:
Volume 3, Issue 4 (Suppl) J Clin Exp Orthop
ISSN:2471-8416 Osteoporosis and Arthroplasty 2017
December 04-05, 2017
&
11th International Conference on
Joint Event
OSTEOPOROSIS, ARTHRITIS & MUSCULOSKELETAL DISORDERS
December 04-05, 2017 | Madrid, Spain
10th INTERNATIONAL CONFERENCE ON ARTHROPLASTY
Bora kim et al., J Clin Exp Orthop 2017, 3:4(Suppl)
DOI: 10.4172/2471-8416-C1-003
Inhibitory effect on epithelial-mesenchymal transition (EMT) by HDAC9 inhibitor in CD133+ prostate
cancer cell line
Bora Kim1, 2 and Wonbong Lim2
1Chonnam National University, South Korea
2Chosun University Hospital, South Korea
One of the theories that a small fraction of cancer cells, defined as cancer stem cells (CSCs), are given rise to differentiated
tumor cells, is proposed to predict tumor recurrence and metastases, providing some support for the concept that CSCs may
be metastatic precursors through epithelial and mesenchymal transition (EMT). In this study, we tried to examine that ectopic
overexpression of CD133 as a key molecule maintaining the stability of CSCs in human prostate cancer cell line, PC-3, DU145 and
LnCaP. In addition, whether the specific inhibitor of simultaneous expressed gene in metastatic category could lead to alleviate the
EMT properties was investigated in CD133 overexpressed PC-3, DU145 and LnCaP. Ectopic over-expressions of CD133 in PC-3,
DU145 led to increase the CSC-related protein expression and colony forming ability in compared with blank GFP transfected cells.
In analysis by microarray, gene expression of HDAC9 was increased simultaneously in CD133 overexpressed PC-3, DU145 and
LnCaP. In addition, inhibition of HDAC9 led the decrease of EMT and metastatic properties sustained with increase of E-cadherin
expression, wound gap distance and cell invasion through inhibition of β-catenin translocation. Taken together, these findings suggest
that inhibition of HDAC9 could plays a functional role in regulating EMT properties in CSC-like prostate cancer and it could be
facilitate study of a novel classification system and therapeutic strategies for metastasis of prostate cancer.
Biography
Bora Kim has graduated from Department of Bioengineering for BS course and Biomedical Engineering for MS course from Chonnam National University, South
Korea and PhD candidate at the same department. Also, as Researcher, with the specialties including Bone Biology, and Carcinogenesis, she has been working at
the Department of Orthopedic Surgery, and Laboratory of Orthopedic Research, Chosun University Hospital in South Korea.